Exceptional response to pazopanib in a patient with urothelial carcinoma harboring FGFR3 activating mutation and amplification

European Urology

Volumn 68, Issue 1, 2015, Pages 168-170

  Palma, Norma ^a   Morris, John C ^b   Ali, Siraj M ^a   Ross, Jeffrey S ^a,c   Pal, Sumanta Kumar ^d  

^a FOUNDATION MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; PACLITAXEL; PAZOPANIB; VINBLASTINE; ANGIOGENESIS INHIBITOR; FGFR3 PROTEIN, HUMAN; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

AGED; BLADDER BIOPSY; BLADDER TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; CYSTOSCOPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE FREQUENCY; GENE MUTATION; HEMATURIA; HISTOPATHOLOGY; HUMAN; KIDNEY DISEASE; LETTER; LUNG LESION; MULTIPLE CYCLE TREATMENT; MULTIPLE PULMONARY NODULES; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; TUMOR VOLUME; CARCINOMA, TRANSITIONAL CELL; GENE AMPLIFICATION; GENETICS; LUNG NEOPLASMS; MUTATION; PATHOLOGY; SECONDARY; URINARY BLADDER NEOPLASMS;

AGED; ANGIOGENESIS INHIBITORS; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MUTATION; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SULFONAMIDES; URINARY BLADDER NEOPLASMS;

EID: 84942989099     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.02.023     Document Type: Letter

References (9)

1. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-31.
2. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005;23:4602-8.
3. Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol 2010;11:861-70.
4. Galsky MD, Chowdhury S, Bellmunt J, et al. Treatment patterns and outcomes in "real world" patients (pts) with metastatic urothelial cancer (UC) [abstract 4525]. J Clin Oncol 2013;31(Suppl).
5. Pili R, Qin R, Flynn PJ, et al. A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 2013;11:477-83.
6. Sequist LV, Cassier P, Varga A. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors [abstract CT326]. Presented at: American Association for Cancer Research annual meeting. San Diego CA USA 2014, April 5-9.
7. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
8. Tomlinson DC, Baldo O, Harnden P, Knowles MA. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 2007;213:91-8.
9. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol 2014;27:271-80.